Beyond the field of cancer therapies, CXCR5 targeting could also be applied for the treatment of autoimmune diseases; we expect selective depletion of mature B cells and of Tfh cells that can promote autoimmunity without impact on precursor B cells. This evidence concerns the gene CXCR5 and autoimmune disease.